Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
NPJ Vaccines|January 17, 2026
Association between COVID-19 vaccine efficacy and epidemic force of infectionJing Xu, M Elizabeth Halloran, Mia Moore, et al.
The New England Journal of Medicine|February 9, 2022
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.SJerald Sadoff, Glenda Gray, An Vandebosch, et al.
The New England Journal of Medicine|January 13, 2021
Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 VaccineJerald Sadoff, Mathieu Le Gars, Georgi Shukarev, et al.
The New England Journal of Medicine|April 21, 2021
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19Jerald Sadoff, Glenda Gray, An Vandebosch, et al.
JAMA|April 20, 2016
Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical TrialIain D Milligan, Malick M Gibani, Richard Sewell, et al.
Nature Medicine|April 3, 2020
Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruptionDonn J Colby, Michal Sarnecki, Dan H Barouch, et al.
The Lancet. HIV|February 21, 2020
Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22)Kathryn E Stephenson, Frank Wegmann, Frank Tomaka, et al.
JAMA Network Open|May 28, 2025
Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data: A Secondary Cross-Protocol Analysis of 5 Randomized Clinical TrialsLeah I B Andrews, M Elizabeth Halloran, Kathleen M Neuzil, et al.
Research Square|July 3, 2023
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence featuresCraig Magaret, Li Li, Allan deCamp, et al.
JAMA|March 11, 2021
Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19Kathryn E Stephenson, Mathieu Le Gars, Jerald Sadoff, et al.
Pageof 5